急性髓系白血病对骨髓的差异性炎症调控及其对疾病进展的影响
研究以膜联蛋白A5(ANXA5)为模型,发现急性髓系白血病(AML)来源的肿瘤坏死因子α(TNF-α)剂量依赖性降低骨髓微环境中的ANXA5,通过前列腺素E2(PGE2)及其EP4受体加速PGE2敏感性AML进展;人骨髓活检显示AML中ANXA5表达较低、PGE2表达较高;同基因和异种移植模型提示塞来昔布联合阿糖胞苷对PGE2高敏感AML有生存获益。
要点
- AML来源的TNF-α剂量依赖性降低骨髓微环境ANXA5,经PGE2/EP4通路加速PGE2敏感性AML。
- 人骨髓活检中AML较其他血液恶性肿瘤ANXA5表达较低、PGE2表达较高。
- 移植模型提示塞来昔布联合阿糖胞苷对PGE2高敏感AML较单用阿糖胞苷有生存获益。
核心结论
- TNF-α/ANXA5/NF-κB/COX2/PGE2介导的炎症以高度差异性和循环方式影响AML病程。
- 作者认为具有「炎症性AML」特征的患者可能从抗炎药物作为辅助治疗中获益。
研究设计与样本
- 研究以小鼠急性髓系白血病与慢性髓系白血病骨髓微环境中差异表达的ANXA5为模型系统。
- 研究使用了同基因和异种移植模型。
- 研究检测了人骨髓环钻活检样本。
主要发现
- AML来源的TNF-α剂量依赖性降低骨髓微环境中的ANXA5,通过升高PGE2水平形成炎症性骨髓微环境。
- PGE2与其EP4受体结合后增加AML细胞中β-连环蛋白和缺氧诱导因子1α信号,从而加速PGE2敏感性AML。
- 人骨髓环钻活检可能显示AML较其他血液恶性肿瘤ANXA5表达较低、PGE2表达较高。
- 同基因和异种移植模型提示,对PGE2高度敏感的AML类型中,塞来昔布联合阿糖胞苷较单用阿糖胞苷有生存获益。
临床怎么用
- 作者认为具有「炎症性AML」特征的患者可能从抗炎药物作为辅助治疗中获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inflammation promotes solid tumor progression, but how regulatory mechanisms of inflammation may affect leukemia is less well studied. Using annexin A5 (ANXA5), a calcium-binding protein known for apoptosis, which we discovered to be differentially expressed in the bone marrow microenvironment (BMM) of mice with acute myeloid (AML) vs chronic myeloid leukemia, as a model system, we unravel here a circuit in which AML-derived tumor necrosis factor α (TNF-α) dose-dependently reduces ANXA5 in the BMM. This creates an inflammatory BMM via elevated levels of prostaglandin E2 (PGE2). Via binding to its EP4 receptor, PGE2 increases β-catenin and hypoxia-inducible factor 1α signaling in AML cells, thereby accelerating PGE2-sensitive AML. Human trephine biopsies may show lower ANXA5 expression and higher PGE2 expression in AML than other hematologic malignancies. Furthermore, syngeneic and xenogeneic transplantation models suggest a survival benefit after treatment with the inhibitor of prostaglandin-endoperoxide synthase 2 (cyclooxygenase 2 [COX2]), celecoxib, plus cytarabine in those AML types highly sensitive to PGE2 compared with cytarabine alone. Taken together, TNF-α/ANXA5/NF-κB/COX2/PGE2-mediated inflammation influences AML course in a highly differential and circular manner, and patients with AML with "inflammatory AML" may benefit from antiphlogistic agents as adjunct therapy.
引用
- Minciacchi VR, Karantanou C, Bravo J, et al. Differential inflammatory conditioning of the bone marrow by acute myeloid leukemia and its impact on progression. Blood Adv. 2024. PMID: 38996202. doi:10.1182/bloodadvances.2024012867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。